M&A Deal Summary |
|
|---|---|
| Date | 2024-08-09 |
| Target | CN201 |
| Sector | Life Science |
| Buyer(s) | Merck |
| Sellers(s) | Curon Biopharmaceutical |
| Deal Type | Divestiture |
| Deal Value | 700M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1891 |
| Sector | Life Science |
| Employees | 70,000 |
| Revenue | 60.1B USD (2023) |
Merck is a global healthcare company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The Company’s operations are comprised of four operating segments. These include Pharmaceutical, Animal Health, Consumer Care and Alliances. Merck's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. Additionally, the Company has consumer care operations that develop, manufacture and market over-the-counter, foot care and sun care products. Merck was established in 1891 and is based in Rahway, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 34 of 34 |
| Sector (Life Science) | 31 of 31 |
| Type (Divestiture) | 2 of 2 |
| Country (China) | 1 of 1 |
| Year (2024) | 3 of 3 |
| Size (of disclosed) | 13 of 27 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-05-29 |
Eyebio
London, United Kingdom Eyebio is a clinical-stage, privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore and improve vision in patients with sight-threatening eye diseases. Eyebio was formed in 2021 and is headquartered in London, England. |
Buy | - |
Curon Biopharmaceutical is a clinical-stage company developing bispecific antibodies and antibody-drug conjugates for the treatment of cancer, from both internal research and external collaborations. Curon Biopharmaceutical was founded in 2018 and is based in Shanghai.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| Country (China) | 1 of 1 |
| Year (2024) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
